New scan could replace biopsies for breast cancer monitoring

NCT ID NCT05412459

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special imaging tracer (99mTc-DARPinG3) to measure HER2 protein levels in breast cancer tumors using SPECT scans. Fifteen women with HER2-positive breast cancer received the tracer before and during chemotherapy plus targeted therapy. The goal was to see if the scan results matched standard tissue biopsies, potentially offering a non-invasive way to track treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 99mTc-DARPinG3 (a radioactive tracer for imaging)
What this could lead to: If successful, this imaging method could help doctors see how well HER2-targeted therapy is working without repeated biopsies.
What could go wrong: This is a very small, early-stage study (15 people) focused on imaging accuracy, not treatment. The method may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FEMALE HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

Tomsk NRMC

Tomsk, Russia
TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.